Kite looks all set for a regulatory approval later this year for its CAR-T drug KTE-CI9 after the company published encouraging topline primary results.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh